| Health / Medical Topics |
HuCC49deltaCH2-PA-DOTA
An immunoconjugate comprised of a humanized monoclonal antibody with antitumor activity. The monoclonal antibody CC49 is developed from the murine monoclonal antibody B72.3 and is humanized by grafting the hypervariable regions onto the variable light (VL) and variable heavy (VH) frameworks of the monoclonal antibodies LEN and 21/28' CL. In addition the CH2 domain in the constant region is deleted to increase plasma clearance. The resultant antibody binds to the pancarcinoma tumor-associated glycoprotein (TAG)-72 with high affinity. Furthermore, the antibody is conjugated to PA-DOTA, a bifunctional chelating agent and commonly radiolabeled, resulting in an effective agent for radioimmunotherapy. (NCI Thesaurus)
YOU MAY ALSO LIKE
A substance being studied in the treatment of some types of cancer. It is made by linking the monoclonal antibody huC242 to…
An immunoconjugate consisting of the anti-tumor cytokine interleukin-12 (IL-12) fused to the tumor-targeting antibody BC1 with potential immunostimulatory and antineoplastic activities. The…
An electronic device designed as a central connection for other devices.
A Chinese herb that has been used as a treatment for a variety of medical problems. It is being studied as an…
A monoclonal antibody being studied in the treatment of several types of cancer. Monoclonal antibodies are made in the laboratory and can…
A traditional Chinese medicine (TCM) containing a water soluble Bufo toad skin extract that includes the cardiac glycosides bufalin, cinobufagin and resibufogenin…
